Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Visual Outcomes of Adding Erythropoietin to Methylprednisolone for Treatment of Retrobulbar Optic Neuritis Publisher



Sanjari MS1 ; Pakdel F5 ; Moosavi F1 ; Pirmarzdashti N2 ; Nojomi M3 ; Haghighi A4 ; Hashemi M1 ; Kashkouli MB1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Ophthalmology Department, Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Ophthalmology Department, Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Community Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Internal Medicine Department, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Ophthalmology Department, Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Qazvin Sq., Tehran, 13366, Iran

Source: Journal of Ophthalmic and Vision Research Published:2019


Abstract

Purpose: To compare the short-term visual function results and safety of erythropoietin as an add-on to the standard corticosteroid therapy in retrobulbar optic neuritis (RON). Methods: In this prospective pilot study, adult patients with isolated RON with less than 10 days of onset were enrolled. Patients were consecutively assigned to standard intravenous methylprednisolone treatment either in combination with intravenous erythropoietin (20,000 units/day for three days) (group-1) or intravenous methylprednisolone alone (group-2). Primary outcome measure was best-corrected visual acuity (BCVA), which was assessed up to 120 days from the day the treatment was begun. Systemic evaluations were performed during and after treatment. Results: Sixty-two patients with RON (mean age = 26.6 ± 5.77 years; range = 18–40 years) were enrolled into the study (group-1, n = 35; group-2, ⁿ = 27). BCVA three months after the treatment was 0.19 ± 0.55 logMAR and 0.11 ± 0.32 logMAR in group-1 and group-2, respectively (95% CI: −0.61 − 0.16; p = 0.62). Change in BCVA after three months was 2.84 ± 3.49 logMAR in group-1 and 2.46 ± 1.40 logMAR in group-2 (95% CI: −0.93−1.91; p = 0.57). Pace of recovery was not significantly different between the groups. No complications were detected among patients. Conclusion: Intravenous erythropoietin as an add-on did not significantly improve the visual outcome in terms of visual acuity, visual field, and contrast sensitivity compared to traditional intravenous corticosteroid. This pilot study supports the safety profile of intravenous human recombinant erythropoietin, and it may help formulate future investigations with a larger sample size. © 2019 Wolters Kluwer Medknow Publications. All rights reserved.
Related Docs
1. Erythropoietin in Treatment of Methanol Optic Neuropathy, Journal of Neuro-Ophthalmology (2018)
2. Optic Canal Decompression in Traumatic Optic Neuropathy, Indian Journal of Clinical and Experimental Ophthalmology (2020)
3. Traumatic Optic Neuropathy Treatment Trial 2 (Tontt-2): Evaluating the Efficacy of Different Doses of Erythropoietin-A Multicentre, Randomised, Double-Blind Clinical Trial, British Journal of Ophthalmology (2024)
4. The Effect of Systemic Erythropoietin and Oral Prednisolone on Recent-Onset Non-Arteritic Anterior Ischemic Optic Neuropathy: A Randomized Clinical Trial, Graefe's Archive for Clinical and Experimental Ophthalmology (2020)
5. Combination of Intravitreal Bevacizumab and Erythropoietin Versus Intravitreal Bevacizumab Alone for Refractory Diabetic Macular Edema: A Randomized Double-Blind Clinical Trial, Graefe's Archive for Clinical and Experimental Ophthalmology (2019)
Experts (# of related papers)
View all Related Experts
Farzad Pakdel (3)
Mehdi Yaseri (2)